enCore Energy Corp. (NASDAQ:EU) is one of the top nuclear energy stocks to invest in for the next 5 years. On March 9, 2026, enCore Energy reported financial and operational results for the year ended December 31, 2025, saying output from its South Texas operations continued to improve as better wellfield efficiency supported stronger uranium extraction. The company extracted 699,807 pounds of U3O8 in 2025, up 242% from 2024, and delivered about 655,000 pounds into contracts at an average selling price of ...

Financial Performance - enCore Energy reported a net loss per share of $(0.30) for the year ended December 31, 2025, compared to $(0.34) for the previous year[3]. - Total sales of U3O8 were approximately 655,000 pounds at an average price of $65.89 per pound, with a weighted average cost of $51.09 per pound[3]. - The total cost of U3O8 sold was $35.335 million for 655,000 pounds, resulting in a cost per pound of $53.95[4]. - Cash costs for extracted pounds were $12.087 million, translating to a cash cost of $29.48 per pound[4]. Production and Operations - The company extracted 699,807 pounds of U3O8 in 2025, representing a 242% increase from 204,000 pounds in 2024[3]. - The company is advancing the Upper Spring Creek Satellite Facility, which is expected to enhance operational flexibility and support future uranium production growth[9]. - Permitting activities for the Dewey Burdock Project are ongoing, with construction expected to commence within the next 18 months[12]. Financial Position and Liquidity - The closing cash and equivalent balance was $52 million, contributing to total liquidity of $96 million at year-end[3]. - During February 2026, enCore exercised approximately 6.6 million warrants, raising approximately $18.1 million to strengthen its financial position[5]. - enCore Energy aims to utilize proceeds from warrant exercises to support project development initiatives, including infrastructure and wellfield development in South Texas[6].

Core Insights - enCore Energy Corp. reported strong operational performance for the year ended December 31, 2025, with significant increases in uranium extraction and liquidity [1] - The company extracted nearly 700,000 pounds of U3O8, marking a 242% increase from the previous year, and achieved a closing liquidity of $96 million [1] - The successful exercise of warrants in February 2026 raised approximately $18.1 million, further strengthening the company's financial position [1] Financial Performance - The closing cash and equivalent balance was $52 million, with a total liquidity of $96 million [1] - The company had an inventory of 132,013 pounds of U3O8 at a cost of $37.77 per pound [1] - Sales of approximately 655,000 pounds of U3O8 were made at a price of $65.89, with a weighted average cost of $51.09 [1] - The net loss per share was $(0.30), an improvement from $(0.34) in the previous year [1] Project Development - Construction activities at the Upper Spring Creek Satellite Facility are ongoing, with some delays due to regulatory approvals from the Texas Commission on Environmental Quality (TCEQ) [1] - The company anticipates completing construction and commencing operations once the remaining approvals are received [1] - The Dewey Burdock Project in South Dakota is progressing through permitting and development planning, with construction expected to start within the next 18 months [1] Strategic Positioning - enCore Energy is focused on expanding domestic uranium production capacity and believes its ISR uranium projects will play a significant role in supporting the U.S. clean energy future [1] - The company is committed to working with local communities and indigenous governments to create positive impacts from its developments [2]

Core Viewpoint - Verdera Energy Corp. has appointed William M. Sheriff as Executive Chair and Director, bringing over 40 years of experience in the minerals and securities industries to the company [1] Company Overview - Verdera Energy Corp. focuses on the development of In-Situ Recovery (ISR) uranium assets in New Mexico, aiming to meet the growing demand for clean and reliable domestic uranium in the United States [1] - The company holds private mineral rights covering approximately 400 square miles and has 88 million pounds of known and historic uranium resources [1] Leadership Background - William M. Sheriff previously served as Executive Chair of enCore Energy Corp., the largest shareholder of Verdera Energy Corp., and has raised over $600 million in public markets [1] - Sheriff has a history of advancing companies in the uranium sector, including founding Energy Metals Corp., which compiled the largest domestic uranium resource base in U.S. history before its sale for $1.8 billion in 2007 [1] - He holds a B.Sc. in Geology and an MSc in Mining Geology, and has compiled one of the largest privately held mining databases globally [1]

Core Points - enCore Energy Corp. plans to distribute common shares of Verdera Energy Corp. to its shareholders following the effectiveness of Verdera's resale registration statement [1] - The company has entered into a Share Purchase Agreement with NM Energy Holding Canada Corp. and Verdera, resulting in the issuance of 50,000,000 non-voting preferred shares of Verdera [1] - enCore intends to convert 35,000,000 of these preferred shares into common shares of Verdera for distribution to its shareholders [1] - Verdera has announced the closing of its CAD$20,000,000 subscription receipt financing, which is part of its business combination with POCML 7 Inc. [1] - The business combination is expected to close on or about February 20, 2026, with trading on the TSX-V to commence on or about February 24, 2026 [1] Company Overview - enCore Energy Corp. is focused on providing clean, reliable, and affordable fuel for domestic nuclear energy and is the only uranium company in the U.S. with multiple operational Central Processing Plants [1] - The company utilizes In-Situ Recovery (ISR) for uranium extraction, a technology co-developed by its industry experts [1] - Future projects in enCore's pipeline include the Dewey Burdock Project in South Dakota and the Gas Hills Project in Wyoming [1]

Core Viewpoint - Verdera Energy Corp. and POCML 7 Inc. have announced the filing of their Filing Statement related to their proposed Qualifying Transaction, which was previously disclosed in November 2025 [1] Group 1 - The Filing Statement was dated February 13, 2026, and is available under POCML7's profile on SEDAR+ [1] - Investors are encouraged to review the Filing Statement for comprehensive details regarding the Transaction [1]

Core Viewpoint - Verdera Energy Corp. and POCML 7 Inc. have successfully closed their offering of subscription receipts, raising a total of $20 million [1] Group 1 - The offering was conducted for aggregate gross proceeds of $20 million [1] - Verdera has reserved the ticker symbol "V" on the TSX Venture Exchange [1] - Trading on the TSX-V is expected to commence on or about February 24, 2026 [1]

Core Insights - Thiogenesis Therapeutics, Corp. announced interim data from its Phase 2 clinical study of TTI-0102 for MELAS at Mitocon 2026, highlighting its potential in treating rare mitochondrial diseases [1][2]. Study Highlights - The Phase 2 (EU) study was a randomized, single-blind, placebo-controlled trial involving nine patients with genetically confirmed MELAS, demonstrating the importance of weight-based dosing for optimal exposure and tolerability [3]. - Fixed dosing led to gastrointestinal adverse events in lower-weight patients, while weight-adjusted dosing mitigated these effects, supporting its use in future trials [6]. Clinical and Pharmacological Findings - Statistically significant improvement in fatigue was observed, with TTI-0102-treated patients showing a mean reduction of up to 10% in the Modified Fatigue Impact Scale (MFIS) score compared to placebo (p < 0.001) [7]. - Weight-based dosing at approximately 60 ± 5 mg/kg achieved sustained 24-hour cysteamine exposure, with lower peak concentrations compared to fixed dosing and approved formulations [6][7]. - Increased plasma pyruvate without lactate elevation suggests enhanced glycolytic flux, indicating improved mitochondrial energy handling [7]. Future Implications - The findings provide a biological rationale for the observed clinical improvement in fatigue and inform the design of upcoming studies, including a Phase 2a study in Leigh syndrome spectrum [8]. - The MFIS is a validated measure for assessing fatigue in mitochondrial disorders, relevant for evaluating therapeutic benefits [9]. Company Overview - Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company focused on developing thiol-based prodrugs for rare pediatric diseases, with TTI-0102 as its lead candidate [14].

Core Viewpoint - Verdera Energy Corp. and POCML 7 Inc. are progressing with a proposed transaction that will qualify as a Qualifying Transaction under TSX Venture Exchange policies, involving a subscription receipt offering to raise $20 million [1][2]. Offering Details - The offering will consist of 20,000,000 Subscription Receipts priced at $1.00 each, with an option for agents to purchase an additional 15% for up to $3 million [2]. - Upon meeting escrow release conditions, each Subscription Receipt will convert into one common share of Verdera [3]. - Agents will receive a 5% commission on gross proceeds and broker warrants equivalent to 4% of the total Subscription Receipts sold [4]. Escrow and Conditions - At closing, gross proceeds will be placed in escrow, with conditions for release including the completion of the proposed transaction [5]. - If conditions are not met within 90 days, funds will be returned to Subscription Receipt holders [5]. - Completion of the proposed transaction is subject to TSXV acceptance and other conditions [8][11]. Use of Proceeds - The net proceeds from the offering will be allocated for exploration and advancement of the Crownpoint and Hosta Butte Project, including drilling, community relations, and general corporate purposes [6]. Company Overview - Verdera Energy Corp. focuses on developing uranium assets in New Mexico, which is the 7th largest uranium-producing district globally, with significant mineral rights in the Grants Uranium District [14]. - The company aims to meet the growing demand for clean domestic uranium through environmentally sound extraction technology [15].

Core Insights - enCore Energy Corp. has appointed Mr. Wayne Heili to its Board of Directors, effective immediately, while Dr. Dennis Stover will retire from the Board on December 31, 2025, but will continue to support the company as Chair of the Technical Advisory Committee [1][2] Company Leadership Changes - Mr. Wayne Heili brings over 35 years of experience in uranium recovery, having held various technical and executive roles in the uranium industry, including CEO positions at Ur-Energy Inc. and Peninsula Energy Limited [3][4] - Dr. Dennis Stover has had a significant impact on the uranium industry over his five-decade career, contributing to safe and sustainable fuel solutions [2] Compensation and Incentives - Upon his appointment, Mr. Heili received an equity award consisting of 25,000 restricted stock units vesting over two years and 100,000 stock options with an exercise price of US$2.73, also vesting over a 24-month period [5] Company Overview - enCore Energy Corp. is focused on providing clean, reliable, and affordable nuclear fuel, being the only U.S. uranium company with multiple Central Processing Plants in operation [6] - The company utilizes In-Situ Recovery (ISR) technology for uranium extraction, which is recognized as a proven method in the industry [6] Future Projects - enCore has plans for future projects, including the Dewey Burdock Project in South Dakota and the Gas Hills Project in Wyoming, building on its success in South Texas [7]